Serum Fetuin-A and Pentraxin3 in hemodialysis and renal transplant patients

Clinical Biochemistry

Volumn 45, Issue 10-11, 2012, Pages 775-779

  Argani, Hassan ^a   Ghorbanihaghjo, Amir ^a   Panahi, Ghodratollah ^a   Rashtchizadeh, Nadereh ^b   Safa, Javid ^a   Meimand, Saeed Mahmoudi ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fetuin A; Hemodialysis; Pentraxin3; Renal transplantation

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FETUIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PENTRAXIN 3; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD VESSEL CALCIFICATION; CHOLESTEROL BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULITIS;

ADULT; ALPHA-2-HS-GLYCOPROTEIN; C-REACTIVE PROTEIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS; SERUM AMYLOID P-COMPONENT;

EID: 84862582341     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.011     Document Type: Article

References (49)

1. Hernandez D., Sanchez-Fructuoso A., Gonzalez-Posada J.M., et al. A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. Transplantation 2009, 88:803-809.
2. Sidhu M.S., Dellsperger K.C. Cardiovascular problems in dialysis patients: impact on survival. Adv Perit Dial 2010, 26:47-52.
3. Tsimihodimos V., Dounousi E., Siamopoulos K.C. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008, 28:958-973.
4. Jeong J.C., Ro H., Hwang Y.H., et al. Cardiovascular diseases after kidney transplantation in Korea. J Korean Med Sci 2010, 25:1589-1594.
5. Yilmaz M.I., Saglam M., Qureshi A.R., et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008, 23:1621-1627.
6. Zoccali C., Mallamaci F., Tripepi G., et al. Prospective study of neuropeptide Y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 2003, 14:2611-2617.
7. Meuwese C.L., Stenvinkel P., Dekker F.W., Carrero J.J. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 2011, 7:166-176.
8. El-Shehaby A.M., Zakaria A., El-Khatib M., Mostafa N. Association of Fetuin-A and cardiac calcification and inflammation levels in hemodialysis patients. Scand J Clin Lab Invest 2010, 70:575-582.
9. Girndt M., Seibert E. Premature cardiovascular disease in chronic renal failure (CRF): a model for an advanced ageing process. Exp Gerontol 2010, 45:797-800.
10. Metry G., Stenvinkel P., Qureshi A.R., et al. Low serum Fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008, 38:804-811.
11. Caplin B., Wheeler D.C. Arterial calcification in dialysis patients and transplant recipients. Semin Dial 2007, 20:144-149.
12. Ketteler M., Brandenburg V., Busch B., et al. Increase of serum Fetuin A concentrations under sevelamer-(SEV) treatment: a prospective crossover study in hemodialysis-(HD) patients. Med Klin 2006, 101:A93.
13. Caglar K., Yilmaz M.I., Saglam M., et al. Serum Fetuin-A concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract 2008, 108:C233-C240.
14. Odamaki M., Shibata T., Takita T., Kumagai H. Serum Fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 2005, 68:2915.
15. Pertosa G., Simone S., Ciccone M., et al. Serum Fetuin A in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?. Am J Kidney Dis 2009, 53:467-474.
16. Chlieper G., Brandenburg V., Djuric Z., et al. Risk factors for cardiovascular calcifications in non-diabetic Caucasian haemodialysis patients. Kidney Blood Press Res 2009, 32:161-168.
17. Chlieper G., Westenfeld R., Brandenburg V., Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial 2007, 20:113-121.
18. Caglar K., Yilmaz M.I., Saglam M., et al. Endothelial dysfunction and Fetuin A levels before and after kidney transplantation. Transplantation 2007, 83:392-397.
19. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
20. Garlanda C., Maina V., Cotena A., Moalli F. The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. J Reprod Immunol 2009, 83:128-133.
21. Han B., Mura M., Andrade C.F., et al. TNF alpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol 2005, 175:8303-8311.
22. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366.
23. Garlanda C., Bottazzi B., Moalli F., et al. Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 2011, 17:38-46.
24. Du Clos T.W., Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fc gamma receptors. Curr Opin Organ Transplant 2011, 16:15-20.
25. Matsui S., Ishii J., Kitagawa F., et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010, 210:220-225.
26. Deban L., Bottazzi B., Garlanda C., de la Torre Y.M., Mantovani A. Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation. Biofactors 2009, 35:138-145.
27. Giang D.T.H., Van Driessche E., Vandenberghe I., Devreese B., Beeckmans S. Isolation and characterization of SAP and CRP, two pentraxins from Pangasianodon (Pangasius) hypophthalmus. Fish Shellfish Immunol 2010, 28:743-753.
28. Mantovani A., Garlanda C., Doni A., Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008, 28:1-13.
29. Gustin C., Delaive E., Dieu M., Calay D., Raes M. Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure. Arterioscler Thromb Vasc Biol 2008, 28:491-497.
30. Tong M., Carrero J.J., Qureshi A.R., et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007, 2:889-897.
31. Yano Y., Matsuda S., Hatakeyama K., et al. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010, 65:547-552.
32. Matsui S., Ishii J., Kitagawa F., et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010, 210:220-225.
33. Ketteler M., Giachelli C. Novel insights into vascular calcification. Kidney Int 2006, 70:S5-S9.
34. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
35. Mantovani A., Garlanda C., Bottazzi B., et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006, 45:326-330.
36. Xu Y., Ding X., Zou J., et al. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients. Ren Fail 2011, 33:998-1004.
37. Malaponte G., Libra M., Bevelacqua Y., et al. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines. Int J Mol Med 2007, 20:471-481.
38. Deban L., Bottazzi B., Garlanda C., de la Torre Y.M., Mantovani A. Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation. Biofactors 2009, 35:138-145.
39. Cozzolino M., Gallieni M., Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. Semin Nephrol 2006, 26:33-37.
40. Gheduzzi D., Boraldi F., Annovi G., et al. Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab Invest 2007, 87:998-1008.
41. Rutsch F., Terkeltaub R. Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. Joint Bone Spine 2005, 72:110-118.
42. Mori K., Motoyama K., Emoto M., et al. Association of serum Fetuin-A-with carotid arterial stiffness in healthy and type-2 diabetic subjects. Diabetes 2006, 55:A160.
43. Jung J.Y., Hwang Y.H., Lee S.W., et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010, 25:4041-4048.
44. Mori K., Ikari Y., Jono S., et al. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis 2010, 21:281-285.
45. Zhang B., Shi W., He C.S., et al. Low serum Fetuin A is a risk factor of coronary artery calcification in patients starting hemodialysis. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:1002-1004.
46. Cozzolino M., Mazzaferro S., Pugliese F., Brancaccio D. Vascular calcification and uremia: what do we know?. Am J Nephrol 2008, 28:339.
47. Moe S.M., Reslerova M., Ketteler M., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005, 67:2295-2304.
48. Suliman M.E., Yimaz M.I., Carrero J.J., et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:976-985.
49. Urbanová M., Kalousová M., Zima T., et al. Fetuin-A early after renal transplantation. Kidney Blood Press Res 2009, 3:217-222.